# Correlation analysis of serum miRNA expression levels with the degree of macular edema in patients with retinal vein occlusion and its clinical implications

**Authors:** Jing Lin, Wei Zhao, Hanyi Zang, Xin Bao

PMC · DOI: 10.3389/fneur.2025.1603790 · Frontiers in Neurology · 2025-07-22

## TL;DR

This study found that specific microRNA levels in blood correlate with the severity of macular edema in retinal vein occlusion patients, suggesting potential use as biomarkers for treatment.

## Contribution

The study identifies serum miR-155-5p, miR-17-5p, and miR-375 as potential biomarkers for macular edema severity and treatment response in retinal vein occlusion.

## Key findings

- miR-155-5p levels were higher in RVO patients compared to healthy controls.
- miR-17-5p and miR-375 levels were lower in RVO patients and correlated with improved visual outcomes after treatment.
- Changes in miRNA levels correlated with macular edema resolution and visual improvement.

## Abstract

To investigate the correlation between serum microRNA (miRNA) levels and the degree of macular edema in retinal vein occlusion (RVO) patients.

180 RVO patients were divided into three groups based on macular edema severity: mild, moderate, and severe. Their serum miR-155-5p, miR-17-5p, and miR-375 levels were compared with 60 healthy controls. Pearson correlation analysis assessed the relationship between miRNA levels and clinical outcomes.

miR-155-5p levels were significantly higher in RVO groups compared to controls, while miR-17-5p and miR-375 levels were lower. Increased severity of macular edema correlated with higher miR-155-5p and lower miR-17-5p and miR-375 levels. After treatment, miR-155-5p levels decreased, while miR-17-5p, miR-375, and visual acuity improved. Correlation analysis showed that changes in miR-155-5p were negatively correlated with visual improvement and macular edema resolution, while miR-17-5p and miR-375 were positively correlated with these outcomes.

Serum miR-155-5p, miR-17-5p, and miR-375 levels are associated with macular edema severity in RVO. These miRNAs may serve as biomarkers for disease progression and prognosis, aiding personalized treatment strategies.

## Linked entities

- **Diseases:** retinal vein occlusion (MONDO:0006951), macular edema (MONDO:0003005)

## Full-text entities

- **Genes:** MIR17 (microRNA 17) [NCBI Gene 406952] {aka MIR17-5p, MIR91, MIRN17, MIRN91, hsa-mir-17, miR-17}, MIR375 (microRNA 375) [NCBI Gene 494324] {aka MIRN375, hsa-mir-375, miRNA375, mir-375}
- **Diseases:** RVO (MESH:D012170), macular edema (MESH:D008269)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12321532/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12321532/full.md

## References

25 references — full list in the complete paper: https://tomesphere.com/paper/PMC12321532/full.md

---
Source: https://tomesphere.com/paper/PMC12321532